![Extension of in vivo half-life of biologically active molecules by XTEN protein polymers - ScienceDirect Extension of in vivo half-life of biologically active molecules by XTEN protein polymers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168365915302054-gr9.jpg)
Extension of in vivo half-life of biologically active molecules by XTEN protein polymers - ScienceDirect
![Addgene: pCAG-rAPOBEC1-gs-XTEN-gs-hdenAsCas12a(E174R/S542R/K548R/D908A)-NLS(nucleoplasmin)-gs-UGI-NLS(SV40)(enAsBE1.1) (RTW1352) Addgene: pCAG-rAPOBEC1-gs-XTEN-gs-hdenAsCas12a(E174R/S542R/K548R/D908A)-NLS(nucleoplasmin)-gs-UGI-NLS(SV40)(enAsBE1.1) (RTW1352)](https://media.addgene.org/data/plasmids/114/114081/114081-map_E37g6w-tMBXJ.png)
Addgene: pCAG-rAPOBEC1-gs-XTEN-gs-hdenAsCas12a(E174R/S542R/K548R/D908A)-NLS(nucleoplasmin)-gs-UGI-NLS(SV40)(enAsBE1.1) (RTW1352)
![Addgene: pCAG-NLS(SV40)x2-rAPOBEC1-gs-XTEN-gs-hdLbCas12a(D832A)-gs-UGI-NLS(SV40)(LbBE1.4) (RTW1293) Sequences Addgene: pCAG-NLS(SV40)x2-rAPOBEC1-gs-XTEN-gs-hdLbCas12a(D832A)-gs-UGI-NLS(SV40)(LbBE1.4) (RTW1293) Sequences](https://media.addgene.org/snapgene-media/v1.7.9-0-g88a3305/sequences/231034/770879cc-d72a-4583-b490-0fc837b49feb/addgene-plasmid-114086-sequence-231034-map.png)
Addgene: pCAG-NLS(SV40)x2-rAPOBEC1-gs-XTEN-gs-hdLbCas12a(D832A)-gs-UGI-NLS(SV40)(LbBE1.4) (RTW1293) Sequences
![Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications | SpringerLink Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10495-021-01686-w/MediaObjects/10495_2021_1686_Fig1_HTML.png)
Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications | SpringerLink
![Evaluation of hyPE2 linker variants. a Detailed information about the... | Download Scientific Diagram Evaluation of hyPE2 linker variants. a Detailed information about the... | Download Scientific Diagram](https://www.researchgate.net/publication/354781925/figure/fig2/AS:1071194929393666@1632404181265/Evaluation-of-hyPE2-linker-variants-a-Detailed-information-about-the-linkers-that-were.png)
Evaluation of hyPE2 linker variants. a Detailed information about the... | Download Scientific Diagram
![Extension of in vivo half-life of biologically active molecules by XTEN protein polymers - ScienceDirect Extension of in vivo half-life of biologically active molecules by XTEN protein polymers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168365915302054-gr8.jpg)
Extension of in vivo half-life of biologically active molecules by XTEN protein polymers - ScienceDirect
![Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors | Nature Cancer Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors | Nature Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs43018-023-00536-9/MediaObjects/43018_2023_536_Fig1_HTML.png)
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors | Nature Cancer
XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to
![XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation | Journal of Nuclear Medicine XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/55/3/508/F3.large.jpg)
XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation | Journal of Nuclear Medicine
![Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility | Bioconjugate Chemistry Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility | Bioconjugate Chemistry](https://pubs.acs.org/cms/10.1021/bc500215m/asset/images/medium/bc-2014-00215m_0002.gif)
Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility | Bioconjugate Chemistry
![Expanding the genome-targeting scope and the site selectivity of high-precision base editors | Nature Communications Expanding the genome-targeting scope and the site selectivity of high-precision base editors | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-020-14465-z/MediaObjects/41467_2020_14465_Fig1_HTML.png)
Expanding the genome-targeting scope and the site selectivity of high-precision base editors | Nature Communications
XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic | PLOS ONE
Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility | Bioconjugate Chemistry
![Addgene: pCAG-rAPOBEC1-gs-XTEN-gs-hdenAsCas12a(E174R/S542R/K548R/D908A)-NLS(nucleoplasmin)-gs-UGI-NLS(SV40)(enAsBE1.1) (RTW1352) Sequences Addgene: pCAG-rAPOBEC1-gs-XTEN-gs-hdenAsCas12a(E174R/S542R/K548R/D908A)-NLS(nucleoplasmin)-gs-UGI-NLS(SV40)(enAsBE1.1) (RTW1352) Sequences](https://media.addgene.org/snapgene-media/v1.7.9-0-g88a3305/sequences/231038/6bcee788-902a-4088-bb5c-9c00530bdc5b/addgene-plasmid-114081-sequence-231038-map.png)
Addgene: pCAG-rAPOBEC1-gs-XTEN-gs-hdenAsCas12a(E174R/S542R/K548R/D908A)-NLS(nucleoplasmin)-gs-UGI-NLS(SV40)(enAsBE1.1) (RTW1352) Sequences
![Generation of highly diverse peptide library by linear-double-stranded DNA based AND gate genetic circuit in mammalian cells | bioRxiv Generation of highly diverse peptide library by linear-double-stranded DNA based AND gate genetic circuit in mammalian cells | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2019/09/19/392498/F6.large.jpg)